Chris Kosmidis

Infectious Diseases Physician and Researcher, University of Manchester. Interested in all aspergillosis clinical syndromes, invasive, allergic and chronic.

[National Aspergillosis Centre @MFT_NAC]

NAC & @mimslearning offer a CPD course about #aspergillosis for GPs, to support them in managing patients with fungal lung conditions 🫁

#respiratory #GPs #pulmonary #respisbest #ABPA #MedEd #CME #NHS

[Martin Hoenigl🇺🇦🇦🇹 @martinhoenigl]

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients - https://t.co/wi95H2giAW

[National Aspergillosis Centre @MFT_NAC]

Would you like to do your #PhD in fungal lung infections? NAC accept applications all year round

✴️Personalised approach to antifungal treatment in chronic fungal lung disease✴️
👉More info at https://t.co/IkYNWVIUjl

#phdjobs #academicjobs #sciencejobs #Manchester #findaphd

[Paul Sax @PaulSaxMD]

One-month treatment for latent tuberculosis.

Why aren't we using it? (Hint: We should.) @NEJM @NEJMClinician
https://t.co/tDOyRiCd30

[James D Chalmers @ProfJDChalmers]

UCB therapeutics announces they will trial anti-IL17/IL-13 multispecific antibody therapy in bronchiectasis in 2026
The pipeline of new therapies coming into the bronchiectasis and COPD field is exciting to see and will ultimately be great for patients.
https://t.co/2MpRKzPOXf

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕⚡🟢Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis
Higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were independently associated with hepatotoxicity.
In multivariable analysis, only pyrazinamide exposure was associated with hepatotoxicity. Rifampicin exposure up to 20 mg/kg/day was not associated with hepatotoxicity, supporting its safe use. #IDXposts https://t.co/oIyrx9WyCP

[National Aspergillosis Centre @MFT_NAC]

Don't worry if you missed #WorldAspergillosisDay - the recordings are now online: https://t.co/Lv1ctJPKcn

Huge thanks to everyone who attended, hope to see you all again next year!

#IDtwitter #medtwitter #respiratory #respisbest #NHS @ckosmidis @MycologyRefManc @aspertrust

[National Aspergillosis Centre @MFT_NAC]

Today is #WorldAspergillosisDay - you can help by sharing this link with any GPs you know

NAC worked with MIMS to produce this CPD course for learning about #aspergillosis to help CPA and #ABPA be diagnosed and treated faster

#respiratory #GPs #pulmonary #respisbest

[Chris Kosmidis @ckosmidis]

Our new paper in Mycoses: Aspergillus serology predicts relapse in chronic pulmonary aspergillosis (#CPA).
End-of-therapy ↑IgG and Aspergillus sensitisation predicted relapse.
👉 Towards personalised follow-up in CPA

https://t.co/cridOTnq61

@MFT_NAC @eurconfmedmycol

[National Aspergillosis Centre @MFT_NAC]

Only 4 days until #WorldAspergillosisDay - have you registered? 🫁
➡️ https://t.co/9rp05h69dV

Pls retweet!
@ckosmidis #respiratory @aspertrust @gaffi_org #ABPA #aspergilloma #idtwitter @EuropeanLung @BTSrespiratory @asthmalunguk @AFWGonline @MycologyRefManc @MRCcmm @MMSNIG

[Chris Kosmidis @ckosmidis]

Looking forward to our 2026 World Aspergillosis Day event!

[National Aspergillosis Centre @MFT_NAC]

Being diagnosed with #aspergillosis can feel isolating and scary

Join the National Aspergillosis Centre (NHS) on Tues 3rd Feb for a free online patient meeting to share experiences, tips and research

#lunghealth #chronicillness @EuropeanLung #copd #abpa #aspergilloma #lungs

[National Aspergillosis Centre @MFT_NAC]

Registration for NAC's #WorldAspergillosisDay meeting is now open!
👉https://t.co/ht8vqNJewT

🗓️Tues 3 Feb

- Antifungal resistance
- CPA risk genes
- Adrenal insufficiency
- Current aspergillosis clinical trials

#idtwitter @aspertrust @MycologyRefManc @ckosmidis @UofMMFIG

[Chris Kosmidis @ckosmidis]

🫁 Chronic pulmonary aspergillosis + OPAT

Our new JAC-AMR paper describes successful treatment with once-weekly rezafungin in a patient with #CPA, with improved convenience and potential cost savings vs daily echinocandins.

https://t.co/k6gxHi6Wjw
@MFT_NAC
@MundipharmaTalk

[Chris Kosmidis @ckosmidis]

Deadline approaching soon!

[Chris Kosmidis @ckosmidis]

Delighted to share we are recruiting for a Fully Funded PhD "Personalised Approach to Treatment of Chronic Fungal Lung Disease" at the @MFT_NAC and @FBMH_UoM as part of the MRC DTP studentship programme!
More info: https://t.co/pn6UVLq2My
Please get in touch before applying.

[Chris Kosmidis @ckosmidis]

Delighted to share we are recruiting for a Fully Funded PhD "Personalised Approach to Treatment of Chronic Fungal Lung Disease" at the @MFT_NAC and @FBMH_UoM as part of the MRC DTP studentship programme!
More info: https://t.co/pn6UVLq2My
Please get in touch before applying.

[Norman van Rhijn @NormanRhijn]

🚨PhD opportunity

The China Scholarship Council (CSC-UoM) Joint Scholarship Programme is to support outstanding Chinese researchers for PhD studies at the University of Manchester and nominations are now open.

More information can be found at: https://t.co/CQMnZUHZhg

[Chris Kosmidis @ckosmidis]

Ritesh Agarwal at @eurconfmedmycol meeting: important to recognise #ABPA and treat early with steroids and antifungals to preserve lung function @MFT_NAC

[Chris Kosmidis @ckosmidis]

Sara Gago at @eurconfmedmycol meeting: Aspergillus in lungs of severe COVID-19 patients linked to poor outcomes @MFT_NAC